# A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

> **NCT06948747** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 49 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** AZD5004
- **DRUG:** Rosuvastatin
- **DRUG:** Erythromycin
- **DRUG:** Atorvastatin
- **DRUG:** Simvastatin
- **DRUG:** Repaglinide

## Key facts

- **NCT ID:** NCT06948747
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-06
- **Primary completion:** 2025-10-03
- **Final completion:** 2025-10-03
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06948747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06948747, "A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06948747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*